Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Association Between CYP1A1 Polymorphisms and Risk of Bladder Cancer: a Meta-analysis

  • Lu, Yu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Zhang, Xiao-Lian (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Xie, Li (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Tai-Jie (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • He, Yu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Peng, Qi-Liu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Deng, Yan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Wang, Jian (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Qin, Xue (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Shan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The effects of CYP1A1 gene polymorphisms on the risk of bladder cancer (BC) remain controversial. We carried out a meta-analysis to clarify the role of CYP1A1 gene polymorphisms in BC. Material and Methods: A comprehensive literature search was conducted up to November 20, 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the strength of the association. Meta-regression, subgroup analysis, sensitivity analysis and publication bias were also performed. Results: Eight studies involving 1,059 BC cases and 1,061 controls were included. The meta-analysis showed that there was no significant association between the two common mutations of CYP1A1 and BC risk. For the I1e462Val A/G polymorphism with GG vs. AA the OR was 1.47 (95 % CI= 0.70-3.07, P =0.308). For the MspI T/C polymorphism, though a slight trend was found this was not statistically nonsignificant (CC vs.TT, OR = 1.24, 95 % CI= 0.98-1.58, P =0.078). Subgroup analyses by ethnicity also found no obvious association between CYP1A1 and BC risk. Conclusion: The present meta-analysis suggests that CYP1A1 polymorphism is not associated with bladder cancer risk.

Keywords

References

  1. Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28.
  2. Berber U, Yilmaz I, Yilmaz O, et al (2013). CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Asian Pac J Cancer Prev, 14, 3925-9. https://doi.org/10.7314/APJCP.2013.14.6.3925
  3. Boffetta P, Jourenkova N, Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-72. https://doi.org/10.1023/A:1018465507029
  4. Bosetti C, Pira ELa Vecchia C (2005). Bladder cancer risk in painters: a review of the epidemiological evidence, 1989-2004. Cancer Causes Control, 16, 997-1008. https://doi.org/10.1007/s10552-005-3636-5
  5. Botelho MC, Machado J, Cda Costa JM (2010). Schistosoma haematobium and bladder cancer: what lies beneath? Virulence, 1, 84-7. https://doi.org/10.4161/viru.1.2.10487
  6. Brockmoller J, Cascorbi I, Kerb R, et al (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 56, 3915-25.
  7. Cascorbi I, Brockmoller J, Roots I (1996). A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res, 56, 4965-9.
  8. Dai LP, Wang YP, Wu XB, et al (2009). Study on the association of cytochrome P450 polymorphisms and the risk of esophageal cancer: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi, 30, 1198-202 (in Chinese).
  9. Dorrenhaus A, Muller TRoos PH (2007). Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. Arch Toxicol, 81, 19-25. https://doi.org/10.1007/s00204-006-0134-9
  10. Fontana L, Delort L, Joumard L, et al (2009). Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res, 29, 1631-5.
  11. Fu Jing CB-c (2013). Relationship between genetic polymorphisms of CYP1A1, NQO1, and EPHX1 and susceptibility to bladder cancer. Chin J Cancer Prev Treat, 20, 10-4.
  12. Giri SK, Yadav A, Kumar A, et al (2012). CYP1A1 gene polymorphisms: modulator of genetic damage in coal-tar workers. Asian Pac J Cancer Prev, 13, 3409-16. https://doi.org/10.7314/APJCP.2012.13.7.3409
  13. Grando JP, Kuasne H, Losi-Guembarovski R, et al (2009). Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med, 9, 21-8. https://doi.org/10.1007/s10238-008-0015-z
  14. Guengerich FP, Shimada T (1998). Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res, 400, 201-13. https://doi.org/10.1016/S0027-5107(98)00037-2
  15. Hayashi S, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem, 110, 407-11. https://doi.org/10.1093/oxfordjournals.jbchem.a123594
  16. Hiyama T, Yoshihara M, Tanaka S, et al (2008). Genetic polymorphisms and head and neck cancer risk (Review). Int J Oncol, 32, 945-73.
  17. Ismail SI, Soubani M, Nimri JM, et al (2013). Cancer incidence in Jordan from 1996 to 2009--a comprehensive study. Asian Pac J Cancer Prev, 14, 3527-34. https://doi.org/10.7314/APJCP.2013.14.6.3527
  18. Ji YN, Wang Q, Suo LJ (2012). CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS One, 7, e43397. https://doi.org/10.1371/journal.pone.0043397
  19. Jiang X, Castelao JE, Yuan JM, et al (2012). Cigarette smoking and subtypes of bladder cancer. Int J Cancer, 130, 896-901. https://doi.org/10.1002/ijc.26068
  20. Karbakhsh M, Dabbagh N, Shabani A, et al (2013). Age at diagnosis in bladder cancer: does opium addiction play a role? Asian Pac J Cancer Prev, 14, 4723-5. https://doi.org/10.7314/APJCP.2013.14.8.4723
  21. Kawajiri K, Eguchi H, Nakachi K, et al (1996). Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res, 56, 72-6.
  22. Kellermann G, Shaw CRLuyten-Kellerman M (1973). Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med, 289, 934-7. https://doi.org/10.1056/NEJM197311012891802
  23. Kogevinas M, t Mannetje A, Cordier S, et al (2003). Occupation and bladder cancer among men in Western Europe. Cancer Causes Control, 14, 907-14. https://doi.org/10.1023/B:CACO.0000007962.19066.9c
  24. Li S, Peng Q, Chen Y, et al (2013). DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk: a meta-analysis. PLoS One, 8, e73448. https://doi.org/10.1371/journal.pone.0073448
  25. Li X, Cui WP, Bai SF (2007). Analysis of the polymorphism of CYP1A1-MSPI gene in patients with bladder cancer. China Prac Med, 2, 3-5. https://doi.org/10.1186/1749-8546-2-3
  26. Lu Y, Peng Q, Zeng Z, et al (2013). CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis. J Neurol Sci, 336, 161-8.
  27. Luch A (2005). Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer, 5, 113-25. https://doi.org/10.1038/nrc1546
  28. Manuguerra M, Matullo G, Veglia F, et al (2007). Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis, 28, 414-22.
  29. Mooney LA, Bell DA, Santella RM, et al (1997). Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis, 18, 503-9. https://doi.org/10.1093/carcin/18.3.503
  30. Murray GI, Taylor VE, McKay JA, et al (1995). Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol, 76, 271-6.
  31. Ozturk T, Kahraman OT, Toptas B, et al (2011). The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo, 25, 663-8.
  32. Peng Q, Mo C, Tang W, et al (2013). DNA repair gene XRCC3 polymorphisms and bladder cancer risk: a meta-analysis. Tumour Biol, 35, 1933-44.
  33. Pollard C, Smith SC, Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med, 12, e10. https://doi.org/10.1017/S1462399410001407
  34. Romkes M, White C, Johnson J, et al (1996). Expression of cytochrome P450 mRNA in human lung, head and neck tumours, and normal adjacent tissues. Proc Am Assoc Cancer Res, 37, 105.
  35. Sergentanis TN, Economopoulos KP (2010). Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 122, 459-69. https://doi.org/10.1007/s10549-009-0694-5
  36. Shakhssalim N, Hosseini SY, Basiri A, et al (2010). Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev, 11, 601-6.
  37. Shimada T (2006). Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet, 21, 257-76. https://doi.org/10.2133/dmpk.21.257
  38. Srivastava DS, Mandhani A, Mittal RD (2008). Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India. Arch Toxicol, 82, 633-9. https://doi.org/10.1007/s00204-007-0276-4
  39. Thakkinstian A, McElduff P, D'Este C, et al (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306. https://doi.org/10.1002/sim.2010
  40. Vineis P, Veglia F, Garte S, et al (2007). Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol, 18, 1230-42. https://doi.org/10.1093/annonc/mdm109
  41. Wahid M, Mahjabeen I, Baig RM, et al (2013). Expression of CYP1A1 and GSTP1 in human brain tumor tissues in Pakistan. Asian Pac J Cancer Prev, 14, 7187-91. https://doi.org/10.7314/APJCP.2013.14.12.7187
  42. Wolf A, Kutz A, Plottner S, et al (2005). The effect of benzo (a)pyrene on porcine urinary bladder epithelial cells analyzed for the expression of selected genes and cellular toxicological endpoints. Toxicology, 207, 255-69. https://doi.org/10.1016/j.tox.2004.09.006
  43. Yang XQ, Xu C, Sun Y, et al (2013). Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9. https://doi.org/10.7314/APJCP.2013.14.4.2583
  44. Zeegers MP, Tan FE, Dorant E, et al (2000). The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer, 89, 630-9. https://doi.org/10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q

Cited by

  1. Influence of the CYP1A1 T3801C Polymorphism on Tobacco and Alcohol-Associated Head and Neck Cancer Susceptibility in Northeast India vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6953